Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Q1 2018 · 10-Q
Revenue$357.08M$357.08M+38.1% vs Q1 2017 Net Income$10.99M$10.99M+71.9% vs Q1 2017 EPS Diluted$0.14$0.14+75.0% vs Q1 2017 Gross Profit$212,860,000+23.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
Operating Cash Flow$41,531,000+43.8% Free Cash Flowderived$26,144,000+32.8% Margins · derivedGross margin59.6%−6.9 pt vs Q1 2017
Operating margin7.2%+3.3 pt vs Q1 2017
Net margin3.1%+0.6 pt vs Q1 2017
ended Mar 31, 2018 · filed Apr 26, 2018 · 26 d after period end